A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania

Human Psychopharmacology

Volumn 20, Issue 2, 2005, Pages 133-139

  Frey, Benício N ^a,b,g   Folgierini, Marcelo ^c   Nicoletti, Mark ^d   Machado Vieira, Rodrigo ^e   Stanley, Jeffrey A ^f   Soares, Jair C ^d   Kapczinski, Flávio ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL MÃE DE DEUS   (Brazil)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g NONE   (Brazil)

Author keywords

Bipolar disorder; Dorsolateral prefrontal cortex; Mania; Mood disorders; Neuroimaging; Proton magnetic resonance spectroscopy

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; INOSITOL; MOOD STABILIZER; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; PHOSPHATIDYLINOSITIDE;

ACUTE DISEASE; ADULT; ARTICLE; BIPOLAR DISORDER; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTERVIEW; LONGITUDINAL STUDY; MALE; MANIA; MOOD DISORDER; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; VOLUNTEER;

ACUTE DISEASE; ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; BIPOLAR DISORDER; CHOLINE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; INOSITOL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PATIENT SELECTION; PHOSPHOCREATINE; PREFRONTAL CORTEX;

EID: 14944385272     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.671     Document Type: Article

References (49)

1. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS. 1998. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic-depressives. Biol Psychiatry 44: 88-97.
2. Bertolino A, Callicott JH, Mattay VS, et al. 2001. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 49: 39-46.
3. Bertolino A, Frye M, Callicott JH, et al. 2003. Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biol Psychiatry 53: 906-913.
4. Bezchlibnyk Y, Young LT. 2002. The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression. Can J Psychiatry 47: 135-148.
5. Blazer DG. 2000. Mood disorders: epidemiology. In Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 7th edn, Sadock BJ, Sadock VA (eds). Lippincott Williams & Wilkins: Philadelphia; 1298-1308.
6. Brown AS, Mallinger AG, Renbaum LC. 1993. Elevated platelet membrane phosphatidylinositol-4,5-biphosphate in bipolar mania. Am J Psychiatry 150: 1252-1254.
7. Cecil KM, DelBello MP, Morely R, Strakowski SM. 2002. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord 4: 357-365.
8. Chang K, Adleman N, Dienes K, Barnea-Goraly N, Reiss A, Ketter T. 2003. Decreased N-acetylaspartate in children with familial bipolar disorder. Biol Psychiatry 53: 1059-1065.
9. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. 2000. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 75: 1729-1734.
10. Cotter D, Mackay D, Beasley CL, Everall I, Landau S. 2002. The density, size and spatial distribution of neurons and glia in area 9 prefrontal cortex in schizophrenia, bipolar disorder and major depression. Schizophr Res 53: 107-108.
11. Davanzo P, Thomas A, Yue K, et al. 2001. Decreased anterior cingulate myoinositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 24: 359-369.
12. Davanzo P, Yue K, Thomas MA, et al. 2003. Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. Am J Psychiatry 160: 1442-1452.
13. Deicken RF, Eliaz Y, Feiwell R, et al. 2001. Increased thalamic N-acetylaspartate in male patients with familiar bipolar I disorder. Psychiatry Res 106: 35-45.
14. Deicken RF, Fein G, Weiner MW. 1995. Abnormal frontal lobe phosphorus metabolism in bipolar disorder. Am J Psychiatry 152 915-918.
15. Drevets WC, Price JL, Simpson JR, Jr, et al. 1997. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386: 824-827.
16. First MB, Spitzer RL, Gibbon M, Williams JB. 1998. Structured Clinical Interview for DSM-IV (SCID-I). Biomedics Research Department: New York.
17. Friedman E, Hoau YW, Levinson D, Connell TA, Singh H. 1993. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 33: 520-525.
18. George MS, Ketter TA, Post RM. 1994. Prefrontal cortex dysfunction in clinical depression. Depression 2: 59-72.
19. Goodwin FK, Jamison KR (eds). Manic-Depressive Illness. Oxford University Press: New York, 1990.
20. Guy W. Early Clinical Drug Evaluation until Assessment Manual for Psychopharmacology. Revised Edition. Department of Health, Education, and Welfare: Washington DC, 1976.
21. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
22. Jope RS, Song L, Li PP, et al. 1996. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J Neurochem 66: 2402-2409.
23. Kato T, Inubushi T, Kato N. 1998. Magnetic resonance spectroscopy in affective disorders. J Neuropsychiatry Clin Neurosci 10: 133-147.
24. Manji HK, Etcheberrigaray R, Chen G, Olds JL. 1993. Lithium dramatically decreases membrane-associated protein kinase C in the hippocampus: selectivity for the alpha isozyme. J Neurochem 61 2303-2310.
25. Manji HK, Lenox RH. 2000. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 48: 518-530.
26. Martinot JL, Hardy P, Feline A, et al. 1990. Left prefrontal glucose hypometabolism in the depressive state: a confirmation. Am J Psychiatry 147: 1313-1317.
27. Michael N, Erfurth A, Ohrmann P, et al. 2003. Acute mania is accompanied by glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology 168: 344-346.
28. Miller BL, Chang L, Booth R, et al. 1996. In vivo H MRS choline: correlation with in vitro chemistry/histology. Life Sci 58: 1929-1935.
29. Moore CM, Breeze JL, Gruber SA, et al. 2000a. Choline, myoinositol and mood in bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulated cortex. Bipolar Disord 2: 207-216.
30. Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, et al. 1999. Temporal dissociation between lithium-induced changes in frontal lobe myoinositol and clinical response in manic-depressive illness. Am J Psychiatry 156: 1902-1908.
31. Moore GJ, Bebchuk JM, Hasanat K, et al. 2000b. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effect? Biol Psychiatry 48 1-8.
32. Öngur D, Drevets WC, Price JL. 1998. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95: 13290-13295.
33. Provencher SW. 1993. Estimation of metabolite concentration from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679.
34. Rajkowska G, Halaris A, Selemon LD. 2001. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 49: 741-752.
35. Sharma R, Venkatasubramanian PN, Barany M, Davis JM. 1992. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res 8: 43-49.
36. Sherman WR, Gish BG, Honchar MP, Munsell LY. 1986. Effects of lithium on phosphoinositide metabolism in vivo. Fed Proc 45: 2639-2646.
37. Soares JC, Chen G, Dippold CS, et al. 2000. Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: a preliminary study. Psychiatry Res 95: 109-118.
38. Soares JC, Dippold CS, Wells KF, Frank E, Kupfer DJ, Mallinger AG. 2001. Increased platelet membrane phosphatidylinositol-4,5-biphosphate in drug-free bipolar patients. Neurosci Lett 299: 150-152.
39. Soares JC, Krishnan RR, Keshavan MS. 1996. Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders. Depression 4: 14-30.
40. Soares JC, Mallinger AG, Dippold CS, Frank E, Kupfer DJ. 1999. Platelet membrane phospholipids in euthymic bipolar disorder patients: are they affected by lithium treatment? Biol Psychiatry 45: 453-457.
41. Soares JC, Mann J. 1997. The functional neuroanatomy of mood disorders. J Psychiatr Res 31: 393-432.
42. Stanley JA. 2002. In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders. Can J Psychiatry 47: 315-326.
43. Stanley JA, Pettegrew JW, Keshavan MS. 2000. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings - part 1. Biol Psychiatry 48: 357-368.
44. Strakowski SM, DelBello MP, Adler C, Cecil KM, Sax KW. 2000. Neuroimaging in bipolar disorder. Bipolar Disord 2: 148-164.
45. Urenjak J, Williams SR, Gadian DG, Noble M. 1993. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13: 981-989.
46. Wang HY, Friedman E. 1996. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 40: 568-575.
47. Weinberger DR. 1993. A connectionist approach to the prefrontal cortex. J Neuropsychiatr Clin Neurosci 5: 241-253.
48. Winsberg ME, Sachs N, Tate DL, Adalsteinsson E, Spielman D, Ketter TA. 2000. Decreased dorsolateral prefrontal N-acetylaspartate in bipolar disorder. Biol Psychiatry 47: 475-481.
49. Young RC, Biggs JT, Ziegler VE, Meyer DA. 1978. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 133: 429-435.